# First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

> **NCT01697072** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 609 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Rilotumumab
- **OTHER:** Placebo
- **DRUG:** Epirubicin
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01697072
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2014-11
- **Final completion:** 2015-08
- **Target enrollment:** 609 (ACTUAL)
- **Why stopped:** All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
- **Last updated:** 2016-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01697072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01697072, "First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01697072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*